https://www.selleckchem.com/pr....oducts/epacadostat-i
Whereas European guidelines recommend adjusting lipid-lowering therapy (LLT) to meet prespecified targets ('treat-to-target' for low-density lipoprotein cholesterol (LDL-C), other guidelines do not ('fire and forget'. In a large observational prospective cohort, we sought to evaluate which strategy could be associated with better cardiovascular outcomes in chronic kidney disease (CKD). In CKD-REIN, patients (CKD stages 3 and 4) on LLT were categorized according to achievement of LDL-C targets for high and very high card
Like
Comment
Share
